Pulsed immune reconstitution therapy in multiple sclerosis

Keyphrases

• Multiple Sclerosis 100%
• Alemtuzumab 100%
• Immune Reconstitution 100%
• Cladribine 60%
• Magnetic Resonance Imaging 40%
• Lymphocytes 40%
• Treatment Effect 20%
• Adverse Effects 20%
• Multiple Sclerosis Treatment 20%
• Active Treatment 20%
• Drug Use 20%
• Beneficial Effects 20%
• High Disease Activity 20%
• Mechanism of Action 20%
• Relapsing-remitting multiple Sclerosis 20%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 20%
• Initial Treatment 20%
• Short-term Treatment 20%
• Treatment Course 20%
• Effective Therapy 20%
• T Cells 20%
• Tuberculosis 20%
• CD4+ T Cells 20%
• Immunosuppressive Therapy 20%
• B Lymphocytes 20%
• Disease-modifying Therapy 20%
• Herpes Zoster 20%
• Therapeutic Effect 20%
• Memory B Cells 20%
• Highly Effective 20%
• Latent Infection 20%
• Repletion 20%
• Common Mechanisms 20%
• Prolonged Treatment 20%
• De-escalation Therapy 20%
• Disability Worsening 20%
• Immune-mediated Disorders 20%
• CD19+ 20%

Medicine and Dentistry

• Multiple Sclerosis 100%
• Alemtuzumab 100%
• Immune Reconstitution 100%
• Cladribine 60%
• Magnetic Resonance Imaging 40%
• Lymphocyte 40%
• Disease 20%
• Disease Activity 20%
• Adverse Event 20%
• Infection 20%
• Immunosuppressive Treatment 20%
• Autologous Hematopoietic Stem Cell Transplantation 20%
• Treatment Effect 20%
• T Cell 20%
• T-Helper Cell 20%
• B Lymphocyte 20%
• Disseminated Herpes Zoster 20%
• Short Course Therapy 20%
• Therapy Effect 20%
• Disease Modifying Therapy 20%
• Memory B Cell 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Sclerosis 100%
• Alemtuzumab 100%
• Cladribine 60%
• Disease 40%
• Disease Activity 20%
• Adverse Event 20%
• Infection 20%
• Immunosuppressive Agent 20%
• Therapeutic Effect 20%
• Herpes Zoster 20%